Press "Enter" to skip to content

Glaukos Corp. with UV Corneal Drug Activation Delivers 10-K Annual Report to the SEC

Glaukos Corp. 10-K Annual Report covering 2022 ending 12/31/22 delivered to the SEC on February 24, 2023.See filing at: https://tinyurl.com/2ozzx2r9Critical Accounting Policies and Significant EstimatesManagement’s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles…

This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.